Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KATHLEEN M SCHMELER and KAREN H LU.
KATHLEEN M SCHMELER
Connection Strength
3.159
KAREN H LU
  1. Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol. 2010 Feb; 115(2 Pt 2):432-434.
    View in: PubMed
    Score: 0.358
  2. Endometrial cancer in an adolescent: a possible manifestation of Cowden syndrome. Obstet Gynecol. 2009 Aug; 114(2 Pt 2):477-479.
    View in: PubMed
    Score: 0.346
  3. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl Oncol. 2008 Jun; 10(6):313-7.
    View in: PubMed
    Score: 0.319
  4. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
    View in: PubMed
    Score: 0.283
  5. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19; 354(3):261-9.
    View in: PubMed
    Score: 0.271
  6. Endometrial cancer in young, normal-weight women. Gynecol Oncol. 2005 Nov; 99(2):388-92.
    View in: PubMed
    Score: 0.262
  7. A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges. Fam Cancer. 2011 Jun; 10(2):193-7.
    View in: PubMed
    Score: 0.098
  8. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 2011 Apr; 204(4):355.e1-7.
    View in: PubMed
    Score: 0.096
  9. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010 May; 115(5):945-952.
    View in: PubMed
    Score: 0.091
  10. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol. 2008 Oct; 112(4):835-42.
    View in: PubMed
    Score: 0.082
  11. Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. Int J Gynecol Cancer. 2008 Mar-Apr; 18(2):329-38.
    View in: PubMed
    Score: 0.078
  12. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):146-51.
    View in: PubMed
    Score: 0.074
  13. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol. 2007 Mar; 196(3):247.e1-5.
    View in: PubMed
    Score: 0.073
  14. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int J Gynecol Cancer. 2006 Jul-Aug; 16(4):1668-72.
    View in: PubMed
    Score: 0.070
  15. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006 Jun 01; 106(11):2376-81.
    View in: PubMed
    Score: 0.069
  16. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005 Dec 20; 23(36):9344-50.
    View in: PubMed
    Score: 0.067
  17. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005 Mar; 105(3):575-80.
    View in: PubMed
    Score: 0.064
  18. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 10.
    View in: PubMed
    Score: 0.061
  19. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Apr 12; 5(4):311-320.e3.
    View in: PubMed
    Score: 0.060
  20. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel). 2021 Feb 24; 13(5).
    View in: PubMed
    Score: 0.048
  21. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1733-1737.
    View in: PubMed
    Score: 0.047
  22. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.046
  23. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
    View in: PubMed
    Score: 0.041
  24. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
    View in: PubMed
    Score: 0.039
  25. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55.
    View in: PubMed
    Score: 0.030
  26. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer. 2011 Dec; 10(4):673-9.
    View in: PubMed
    Score: 0.025
  27. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
    View in: PubMed
    Score: 0.024
  28. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer. 2006 Dec 15; 107(12):2745-51.
    View in: PubMed
    Score: 0.018
  29. Are women ready for the HPV vaccine? Gynecol Oncol. 2006 Oct; 103(1):151-4.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.